Entering text into the input field will update the search result below

Top 10 Of 53 Dividend Aristocrats Yield 3.4%-6.2% In July Update

Jul. 11, 2018 5:41 PM ETABBV, APD, CAH, CVX, DOV, ED, JNJ, KMB, KO, MCD, PEP, PG, T, WBA, XOM3 Comments


  • The 53 Aristocrats stocks represent all 11 Morningstar sectors. Broker target top 10 net gains ranged from 12.8% to 20.6%.
  • By yield, AT&T remained the top Aristocrat of 10. Their yields averaged 3.96%.
  • Aristocrats top 10 firms by broker target price upsides averaged 15.2% estimated one-year price gains.
  • $5k invested in the lowest-priced five July top-yield Aristocrats showed 6.7% more net gains than from $5k invested in all ten.

Actionable Conclusions (1-10): Analysts Cast 16% To 29.2% Net Gains To June 2019

Five of ten top Aristocrats by yield were verified as being among the top ten gainers for the coming year based on analyst 1-year target prices (they are tinted gray in the chart above). Thus, our yield-based forecast for Aristocrats was graded by Wall St. wizards as 50% accurate.

Projections based on estimated dividend returns from $1000 invested in each of the thirty highest yielding stocks and their aggregate one year analyst median target prices, as reported by YCharts, created the 2018-19 data points. Note: one year target prices by lone analysts were not applied. Ten probable profit-generating trades projected to July 9, 2019 were:

AT&T Inc. (T) was projected to net $205.51, based on a median of target estimates from thirty-one analysts, plus dividends, less broker fees. The Beta number showed this estimate subject to volatility 58% less than the market as a whole.

Cardinal Health (CAH) was projected to net $199.76 based on dividends, plus a median target estimate from nineteen brokers, less transaction fees. The Beta number showed this estimate subject to volatility 1% more than the market as a whole.

Air Products & Chemicals (APD) was projected to net $189.07, based on target price estimates from twenty analysts, plus annual dividend, less broker fees. The Beta number showed this estimate subject to volatility 20% more than the market as a whole.

AbbVie (ABBV) was projected to net $184.04, based on dividends, plus median target price estimates from twenty-three analysts, less broker fees. The Beta number showed this estimate subject to volatility 62% more than the market as a whole.

Dover (DOV) netted $174.84 based on a median target price estimate from eighteen analysts, plus dividends, less broker fees. The Beta number showed this estimate subject to

Two of these top Arisocrats pups by yield qualify as valuable catches! Find them among the now 52 Dogs of the Week I found on The Dividend Dog Catcher premium site, or the 52 Dogs of the Week II now accumulating. A Dogs of the Week III (A Safari To Sweet Success) portfolio launched Sept. 8 and has 44 selected. Click here to subscribe or get more information.

Make investing gains again. Catch your underdog on Facebook!

At 8:45 a.m. ET nearly every NYSE trading day on Facebook, Dividend Dog Catcher Fredrik Arnold does a quick live video summary of one of four or five stocks contending for a weekly slot in his Safari To Sweet Success portfolio. Just go to Facebook/Dividend Dog Catcher most trading days and watch, like, comment and share the live video. Or catch the replays at any time.

Yet, always remember: Root for the Underdog.

This article was written by

Fredrik Arnold profile picture

Fredrik Arnold is a retired quality service analyst sharing investment ideas with a primary focus on dividend yields by utilizing free cash flow and one-year total returns as trading indicators.

He is the leader of the investing group The Dividend Dog Catcher, where he shares a minimum of one new dividend stock idea per week with focus on yield or extraordinary financial circumstances. All ideas are archived and available after weekly announcement. Learn more.

Analyst’s Disclosure: I am/we are long T. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Recommended For You

Comments (3)

I'll look for a divy cut to support the debt, just like Frontier....
great opportunity to buy
Chester the Income Investor profile picture
T looks like a buy here. Accumulating
Disagree with this article? Submit your own. To report a factual error in this article, . Your feedback matters to us!

Related Stocks

SymbolLast Price% Chg
AbbVie Inc.
Air Products and Chemicals, Inc.
Cardinal Health, Inc.
Chevron Corporation
Dover Corporation

Related Analysis

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.